trial

A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

NCTId NCT05119894
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Withdrawn
Enrollment 0 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2021-12-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Sequential
Masking
None
Start
2021-11-22
Primary completion
2021-12-06
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Takehisa MatsumaruStudy Director

Sites

0 total

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE1
Primary Completion Date
2021-12-06
Status
WITHDRAWN
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Takehisa Matsumaru
person